Montana's SB535 and a Potential Biotech Renaissance in America

Montana's SB535, signed into law in May 2025, authorizes investigational drugs that have cleared Phase I trials to be prescribed and sold, bypassing the traditional FDA approval pathway. The law makes Montana the first state to license experimental treatment centers, positioning it as a highly attractive location for biopharma and life sciences.